Faron Pharmaceuticals (original) (raw)
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland. The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy. In 2020 was selected to take part in the WHO Solidarity trial and trials to find drugs for the symptoms of Covid_19. In June 2020, Faron received a €2,100,000 low interest rate loan from Business Finland for Traumakine manufacturing.
| Property | Value |
|---|---|
| dbo:abstract | Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland. The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy. Its lead product Traumakine has been developed to treat Acute Respiratory Distress Syndrome (ARDS). It is currently (2020) undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS. In 2020 was selected to take part in the WHO Solidarity trial and trials to find drugs for the symptoms of Covid_19. In June 2020, Faron received a €2,100,000 low interest rate loan from Business Finland for Traumakine manufacturing. Faron’s other products include the anti-Clever-1 antibody Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Current encouraging phase I/II clinical trials in Europe are soon to be extended to America. In 2020, the trials continue with bowel cancer and other types of cancer. According to the Faron CEO Markku Jalkanen, the first marketing authorisations could potentially be applied for in 2022–2023. In April 2020, the placing of Faron's shares raised €14 million, and with these resources, Faron will expand the Clevegen study to include several difficult types of cancer, e.g. bowel cancer, ovarian cancer, hepatic cancer and pancreatic cancer. Faron Pharmaceuticals is listed in London on the London Stock Exchange's Alternative Investment Market (AIM). The company is listed secondarily in Helsinki on the Nasdaq First North Growth Market Finland since December 2019. According to the Faron CEO Markku Jalkanen, a secondary listing will enhance the company’s visibility and facilitate the trading of the stock for Scandinavian shareholders. In May 2020, the national research and innovation project Cancer IO received EUR 10 million in funding from Business Finland's personalized health program, of which EUR 800,000 was funded by Faron Pharmaceuticals and in June 2020 Faron received a EUR 2.1 million low-interest loan from Business Finland for the production of the Traumakine drug. (en) |
| dbo:foundedBy | dbr:Markku_Jalkanen |
| dbo:foundingYear | 2003-01-01 (xsd:gYear) |
| dbo:industry | dbr:Healthcare dbr:Biopharmaceutical |
| dbo:keyPerson | dbr:Chief_Executive_Officer dbr:Markku_Jalkanen |
| dbo:location | dbr:Turku |
| dbo:product | dbr:Clevegen dbr:Traumakine |
| dbo:type | dbr:Public_company |
| dbo:wikiPageExternalLink | http://www.faron.com/ |
| dbo:wikiPageID | 62520612 (xsd:integer) |
| dbo:wikiPageLength | 5968 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1105235257 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Public_company dbr:Clevegen dbr:Turku dbr:STAB1 dbr:Acute_Respiratory_Distress_Syndrome dbr:Alternative_Investment_Market dbr:FDA dbr:Healthcare dbc:Pharmaceutical_companies_established_in_2003 dbr:Chief_Executive_Officer dbr:Biopharmaceutical dbc:Pharmaceutical_companies_of_Finland dbr:Markku_Jalkanen dbr:Nasdaq_First_North dbr:Solidarity_trial dbr:Traumakine dbr:REMAP-CAP |
| dbp:foundation | 2003 (xsd:integer) |
| dbp:founder | Markku Jalkanen and others (en) |
| dbp:homepage | http://www.faron.com/ |
| dbp:industry | dbr:Healthcare dbr:Biopharmaceutical |
| dbp:keyPeople | (CEO) (en) Markku Jalkanen (en) |
| dbp:location | Turku, Finland (en) |
| dbp:name | Faron Pharmaceuticals (en) |
| dbp:products | Traumakine, Clevegen (en) |
| dbp:type | dbr:Public_company |
| dbp:wikiPageUsesTemplate | dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Expand_Finnish dbt:AIM |
| dct:subject | dbc:Pharmaceutical_companies_established_in_2003 dbc:Pharmaceutical_companies_of_Finland |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland. The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy. In 2020 was selected to take part in the WHO Solidarity trial and trials to find drugs for the symptoms of Covid_19. In June 2020, Faron received a €2,100,000 low interest rate loan from Business Finland for Traumakine manufacturing. (en) |
| rdfs:label | Faron Pharmaceuticals (en) |
| owl:sameAs | wikidata:Faron Pharmaceuticals dbpedia-fi:Faron Pharmaceuticals https://global.dbpedia.org/id/65fwQ |
| prov:wasDerivedFrom | wikipedia-en:Faron_Pharmaceuticals?oldid=1105235257&ns=0 |
| foaf:homepage | http://www.faron.com/ |
| foaf:isPrimaryTopicOf | wikipedia-en:Faron_Pharmaceuticals |
| foaf:name | Faron Pharmaceuticals (en) |
| is dbo:wikiPageWikiLink of | dbr:List_of_pharmaceutical_companies dbr:Clevegen dbr:Acute_respiratory_distress_syndrome dbr:Markku_Jalkanen dbr:COVID-19_drug_repurposing_research dbr:Nasdaq_Helsinki |
| is foaf:primaryTopic of | wikipedia-en:Faron_Pharmaceuticals |